E6/E7 mRNA检测在高危型人乳头瘤病毒DNA阳性且细胞学轻度异常患者随访中的作用

Abstract
Figure/Table
References (0)
Related Citation (13)

Download: PDF (1348 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the prognostic value of E6/E7 mRNA in the follow-up of patients with high-risk human papillomavirus (HPV) DNA positive and with atypical squamous cell of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL) in cytologic test. Methods: Altogether 332 female patients with ASCUS or LSIL detected by Thin prep cytologic test (TCT) and high-risk HPV DNA positive from January 2015 to December 2015 were collected at the outpatient of Yuyao People’s Hospital. All patients underwent HPV E6/E7 mRNA detection, colposcopic biopsy and pathological examination. The patients whose pathology was CINII- were followed up for 24 months. Kaplan-Meier method was used to analyze the disease progression rate of HPV E6/E7 mRNA positive and negativegroups. Results: Of 332 patients, 277 (83.43%) were CINII- and 55 (16.57%) were CINII+. After 24-months follow-up of 257 patients with CINII-, the percentage of developing CINII+ in E6/E7 mRNA positive group (33/158, 20.89%) was significantly higher than that in negative group (7/99, 7.07%) , and the difference of cumulative disease progression rate in 24 months was statistically significant (χ2=9.966, P=0.002). HPV E6/E7 mRNA detection predicted the specificity of CINII+ to be 42.4 %, the positive predictive value was 22.4%, and the negative predictive value was 93.2%. Conclusion: HPV E6/E7 mRNA testing may be of value to select high-risk HPV DNA positive women with mild cytology in need of immediate referral for colposcopy.

Key words： E6/E7 mRNA humanpapillomavirus atypical squamaus cell of undetermined significance low-grade squamous intraepithelial lesions

Received: 14 March 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Lanying
	SHI Yao
	ZHANG Shengzhi
	XU Ying
	HE Yan
	ZHU Xueqiong.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I11/818

[1] 魏丽惠, 赵超. 宫颈癌及其癌前病变的筛查研究进展[J]. 中华妇幼临床医学杂志(电子版), 2016(1): 16-19.
[2] NISHIMURA M, MIYATAKE T, NAKASHIMA A, et al. Clinical significance of atypical squamous cells of undetermined significance among patients undergoing cervical con-ization[J]. Asian Pac J Cancer Prev, 2015, 16(18): 8145-8147.
[3] REID J L, WRIGHT T J, STOLER M H, et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study[J]. Am J Clin Pathol, 2015, 144(3): 473-483.
[4] GUSTINUCCI D, GIORGI R P, CESARINI E, et al. Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening[J]. Am J Clin Pathol, 2016, 145(1): 35-45.
[5] SORBYE S W, FISMEN S, GUTTERBERG T J, et al. HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions[J]. PLoS One, 2014, 9(11): e112934.
[6] DOORBAR J, QUINT W, BANKS L, et al. The biology and life-cycle of human papillomaviruses[J]. Vaccine, 2012, 30 Suppl 5: F55-F70.
[7] MILLER T A, FLOWERS L. Navigating the cervical cancer screening guidelines for women aged older than 65 years[J]. Menopause, 2017, 24(11): 1302-1303.
[8] ASCIUTTOK C, FORSLUND O, BORGFELDT C. Prevalence of high-risk HPV in postmenopausal women with benign cervical cytology - apopulation-based cohort study[J]. Anticancer Res, 2018, 38(7): 4221-4228.
[9] PAN Q J, HU S Y, GUO H Q, et al. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China[J]. Gynecol Oncol, 2014, 133(2): 172-179.
[10] ORIGONI M, CRISTOFORONI P, CARMINATI G, et al. E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective[J]. Ecancermedicalscience, 2015, 9: 533.
[11] PERSSON M, ELFSTROM K M, BRISMAR W S, et al. Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study[J]. PLoS One, 2014, 9(2): e90023.
[12] JOHANSSON H, BJELKENKRANTZ K, DARLIN L, et al. Presence of high-risk HPV mRNA in relation to future high-grade lesions among high-risk HPV DNA positive women with minor cytological abnormalities[J]. PLoS One, 2015, 10(4): e124460.